To validate the clinical relevance of our finding, we analyzed exosomal RNA from plasmas sampled at baseline, and again at progression of disease from 17 EGFR-mutant NSCLC patients enrolled in a multicenter phase II study (Table S4). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.